Literature DB >> 20824368

Involvement of osteopontin in the matrix-degrading and proangiogenic changes mediated by nicotine in pancreatic cancer cells.

Melissa Lazar1, Jennifer Sullivan, Galina Chipitsyna, Qiaoke Gong, Chee Y Ng, Ahmed F Salem, Tamer Aziz, Agnes Witkiewicz, David T Denhardt, Charles J Yeo, Hwyda A Arafat.   

Abstract

BACKGROUND: Substantial evidence indicates that exposure to cigarette smoke is associated with an elevated risk of pancreatic ductal adenocarcinoma (PDA). However, the mechanisms underlying the effects of nicotine on the development or progression of PDA remain to be investigated. Previously, we showed that nicotine promotes the expression of osteopontin c (OPNc), an isoform of OPN protein that confers on cancer cells a migratory phenotype. In this study, we explored the potential prometastatic role of nicotine in PDA through studying its effect on the expression of matrix metalloproteinase-9 (MMP-9) and vascular endothelial growth factor (VEGF) and evaluated the role of OPN in mediating these effects.
MATERIALS AND METHODS: MMP-9 and VEGF mRNA and protein were analyzed in PDA cells treated with or without nicotine (3-300 nM). Transient transfection and luciferase-labeled promoter studies evaluated the effects of OPNc and OPN protein on the transcription and translation of MMP-9 and VEGF. Real-time PCR and immunohistochemistry were used to analyze the mRNA expression levels and localization of OPN, MMP-9, and VEGF proteins in matched invasive human PDA and surrounding nonmalignant tissues. RESULTS AND DISCUSSION: Nicotine significantly enhanced the expression of MMP-9 and VEGF mRNA and protein in PDA cells. Blocking OPN with siRNA or OPN antibody prevented the nicotine-mediated increase of both MMP-9 and VEGF. Transient transfection of OPNc gene in PDA cells or their treatment with recombinant OPN protein significantly (p < 0.05) increased MMP-9 and VEGF mRNA expression levels and induced their promoter activities. In invasive PDA lesions, MMP-9 mRNA levels were significantly (p < 0.005) higher in smokers vs. nonsmokers. VEGF protein co-localized with MMP-9 and OPN in the malignant ducts and correlated well with their higher levels in invasive PDA lesions.
CONCLUSIONS: Our data show for the first time that cigarette smoking and nicotine may contribute to PDA metastasis through inducing MMP-9 and VEGF and suggest that OPN plays a central role in mediating these effects. The presence of OPN as a downstream effector of nicotine that is capable of mediating its prometastatic effects in PDA cells is novel and could provide a unique therapeutic target to control pancreatic cancer aggressiveness, especially in the cigarette-smoking population.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20824368     DOI: 10.1007/s11605-010-1338-0

Source DB:  PubMed          Journal:  J Gastrointest Surg        ISSN: 1091-255X            Impact factor:   3.452


  35 in total

1.  A short-hairpin RNA targeting osteopontin downregulates MMP-2 and MMP-9 expressions in prostate cancer PC-3 cells.

Authors:  Hao Liu; Anmin Chen; Fengjing Guo; Lin Yuan
Journal:  Cancer Lett       Date:  2010-03-06       Impact factor: 8.679

Review 2.  Metabolism and disposition kinetics of nicotine.

Authors:  Janne Hukkanen; Peyton Jacob; Neal L Benowitz
Journal:  Pharmacol Rev       Date:  2005-03       Impact factor: 25.468

3.  Expression of a prometastatic splice variant of osteopontin, OPNC, in human pancreatic ductal adenocarcinoma.

Authors:  Jennifer Sullivan; Laurel Blair; Amer Alnajar; Tamer Aziz; Chee Yuan Ng; Galina Chipitsyna; Qiaoke Gong; Agnes Witkiewicz; Georg F Weber; David T Denhardt; Charles J Yeo; Hwyda A Arafat
Journal:  Surgery       Date:  2009-08       Impact factor: 3.982

4.  An osteopontin fragment is essential for tumor cell invasion in hepatocellular carcinoma.

Authors:  V Takafuji; M Forgues; E Unsworth; P Goldsmith; X W Wang
Journal:  Oncogene       Date:  2007-04-23       Impact factor: 9.867

5.  Cigarette smoking and pancreas cancer: a case-control study based on direct interviews.

Authors:  D T Silverman; J A Dunn; R N Hoover; M Schiffman; K D Lillemoe; J B Schoenberg; L M Brown; R S Greenberg; R B Hayes; G M Swanson
Journal:  J Natl Cancer Inst       Date:  1994-10-19       Impact factor: 13.506

6.  TPS, CA 19-9, VEGF-A, and CEA as diagnostic and prognostic factors in patients with mass lesions in the pancreatic head.

Authors:  Gabriel Sandblom; Sofie Granroth; Ib Christian Rasmussen
Journal:  Ups J Med Sci       Date:  2008       Impact factor: 2.384

Review 7.  Angiogenesis in cancer, vascular, rheumatoid and other disease.

Authors:  J Folkman
Journal:  Nat Med       Date:  1995-01       Impact factor: 53.440

8.  Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer.

Authors:  Y Takahashi; Y Kitadai; C D Bucana; K R Cleary; L M Ellis
Journal:  Cancer Res       Date:  1995-09-15       Impact factor: 12.701

9.  Significance of vessel count and vascular endothelial growth factor and its receptor (KDR) in intestinal-type gastric cancer.

Authors:  Y Takahashi; K R Cleary; M Mai; Y Kitadai; C D Bucana; L M Ellis
Journal:  Clin Cancer Res       Date:  1996-10       Impact factor: 12.531

10.  Increased incidence of cancer in chronic pancreatitis.

Authors:  G Rocca; E Gaia; R Iuliano; M T Caselle; N Rocca; G Calcamuggi; G Emanuelli
Journal:  J Clin Gastroenterol       Date:  1987-04       Impact factor: 3.062

View more
  25 in total

1.  Regulation of pancreatic cancer by neuropsychological stress responses: a novel target for intervention.

Authors:  Hildegard M Schuller; Hussein A N Al-Wadei; Mohammad F Ullah; Howard K Plummer
Journal:  Carcinogenesis       Date:  2011-11-09       Impact factor: 4.944

2.  Clinical significance of serum COL6A3 in pancreatic ductal adenocarcinoma.

Authors:  Christopher Y Kang; Jonathan Wang; Dierdre Axell-House; Pranay Soni; Mon-Li Chu; Galina Chipitsyna; Konrad Sarosiek; Jocelyn Sendecki; Terry Hyslop; Mazhar Al-Zoubi; Charles J Yeo; Hwyda A Arafat
Journal:  J Gastrointest Surg       Date:  2013-09-04       Impact factor: 3.452

Review 3.  SIBLINGs and SPARC families: their emerging roles in pancreatic cancer.

Authors:  Ferda Kaleağasıoğlu; Martin R Berger
Journal:  World J Gastroenterol       Date:  2014-10-28       Impact factor: 5.742

4.  Effects of chronic nicotine on the autocrine regulation of pancreatic cancer cells and pancreatic duct epithelial cells by stimulatory and inhibitory neurotransmitters.

Authors:  Mohammed H Al-Wadei; Hussein A N Al-Wadei; Hildegard M Schuller
Journal:  Carcinogenesis       Date:  2012-07-12       Impact factor: 4.944

5.  Beta-adrenergic signaling in the development and progression of pulmonary and pancreatic adenocarcinoma.

Authors:  Hildegard M Schuller; Hussein A N Al-Wadei
Journal:  Curr Cancer Ther Rev       Date:  2012-05-01

Review 6.  Interplay between smoking-induced genotoxicity and altered signaling in pancreatic carcinogenesis.

Authors:  Navneet Momi; Sukhwinder Kaur; Moorthy P Ponnusamy; Sushil Kumar; Uwe A Wittel; Surinder K Batra
Journal:  Carcinogenesis       Date:  2012-05-23       Impact factor: 4.944

7.  Osteopontin (OPN) isoforms, diabetes, obesity, and cancer; what is one got to do with the other? A new role for OPN.

Authors:  Konrad Sarosiek; Elizabeth Jones; Galina Chipitsyna; Mazhar Al-Zoubi; Christopher Kang; Shivam Saxena; Ankit V Gandhi; Jocelyn Sendiky; Charles J Yeo; Hwyda A Arafat
Journal:  J Gastrointest Surg       Date:  2015-01-13       Impact factor: 3.452

8.  Mechanisms for nicotine in the development and progression of gastrointestinal cancers.

Authors:  Kendal Jensen; Syeda Afroze; Md Kamruzzaman Munshi; Micheleine Guerrier; Shannon S Glaser
Journal:  Transl Gastrointest Cancer       Date:  2012-04

9.  Gamma-amino butyric acid (GABA) prevents the induction of nicotinic receptor-regulated signaling by chronic ethanol in pancreatic cancer cells and normal duct epithelia.

Authors:  Mohammed H Al-Wadei; Hussein A N Al-Wadei; Hildegard M Schuller
Journal:  Cancer Prev Res (Phila)       Date:  2012-12-04

10.  RAN GTPase and Osteopontin in Pancreatic Cancer.

Authors:  Shivam Saxena; Ankit Gandhi; Pei-Wen Lim; Daniel Relles; Konrad Sarosiek; Christopher Kang; Galina Chipitsyna; Jocelyn Sendecki; Charles J Yeo; Hwyda A Arafat
Journal:  Pancreat Disord Ther       Date:  2013-04-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.